CoChat

Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images

Open access
Whitwell, J. L., Boeve, B. F., Weigand, S. D., Senjem, M. L., Gunter, J. L., Baker, M. C., DeJesus‐Hernandez, M., Knopman, D. S., Wszolek, Z. K., Petersen, R. C., Rademakers, R., Jack, C. R., Josephs, K. A. · 2015 · European Journal of Neurology
Cited by 119

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background and purpose: The aim of our study was to determine the utility of longitudinal magnetic resonance imaging (MRI) measurements as potential biomarkers in the main genetic variants of frontotemporal dementia (FTD), including microtubule‐associated protein tau (MAPT) and progranulin (GRN) mutations and C9 ORF 72 repeat expansions, as well as sporadic FTD. Methods: In this longitudinal study, 58 subjects were identified who had at least two MRI and MAPT mutations (n = 21), GRN mutations (n = 11), C9 ORF 72 repeat expansions (n = 11) or sporadic FTD (n = 15). A total of 198 serial MRI measurements were analyzed. Rates of whole brain atrophy were calculated using the boundary shift integral. Regional rates of atrophy were calculated using tensor‐based morphometry. Sample size estimates were calculated. Results: Progressive brain atrophy was observed in all groups, with fastest rates of whole brain atrophy in GRN, followed by sporadic FTD, C9 ORF 72 and MAPT. All variants showed greatest rates in the frontal and temporal lobes, with parietal lobes also strikingly affected in GRN. Regional rates of atrophy across all lobes were greater in GRN compared to the other groups. C9 ORF 72 showed greater rates of atrophy in the left cerebellum and right occipital lobe than MAPT, and sporadic FTD showed greater rates in the anterior cingulate than C9 ORF 72 and MAPT. Sample size estimates were lowest using temporal lobe rates in GRN, ventricular rates in MAPT and C9 ORF 72, and whole brain rates in sporadic FTD. Conclusion: These data support the utility of using rates of atrophy as outcome measures in future drug trials in FTD and show that different imaging biomarkers may offer advantages in the different variants of FTD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/ene.12675

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 19

  1. 10.1097/WAD.0b013e31815c345e · DOI · Paper page
  2. 10.1093/brain/awr361 · DOI · Paper page
  3. 10.1016/j.neuroimage.2009.12.088 · DOI · Paper page
  4. 10.1212/WNL.0b013e318268452e · DOI · Paper page
  5. 10.1212/01.wnl.0000343851.46573.67 · DOI · Paper page
  6. 10.1093/brain/aws001 · DOI · Paper page
  7. 10.1212/WNL.0b013e318227047f · DOI · Paper page
  8. 10.1093/hmg/ddl241 · DOI · Paper page
  9. 10.1001/archneur.63.4.506 · DOI · Paper page
  10. 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
  11. 10.1212/WNL.34.7.939 · DOI · Paper page
  12. 10.1016/j.neuroimage.2004.04.030 · DOI
  13. 10.1109/42.640753 · DOI · Paper page
  14. 10.1002/jmri.10325 · DOI · Paper page
  15. 10.1016/j.media.2007.06.004 · DOI · Paper page
  16. 10.1212/WNL.0000000000000386 · DOI · Paper page
  17. 10.1006/nimg.2001.0978 · DOI · Paper page
  18. 10.1007/978-1-4419-0318-1 · DOI · Paper page
  19. 10.1212/WNL.0b013e3181b9c8b9 · DOI · Paper page

Cited by

Metadata

Authors
Whitwell, J. L., Boeve, B. F., Weigand, S. D., Senjem, M. L., Gunter, J. L., Baker, M. C., DeJesus‐Hernandez, M., Knopman, D. S., Wszolek, Z. K., Petersen, R. C., Rademakers, R., Jack, C. R., & Josephs, K. A.
Venue
European Journal of Neurology
Publisher
Wiley
Published
2015-02-12
Volume
22
Issue
5
Pages
745-752
ISSN
  • 1351-5101 (ISSN-L)
  • 1468-1331
OpenAlex
W1970578687
Cited by
119
References
8
FWCI
9.41
Type
journal article
Language
en
Open access
green
Funders
  • National Institutes of Health (R01 DC010367, R01 AG11378, P50 AG016574)
  • Alzheimer's Association (NIRG-12-242215)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.